BerGenBio initiates lung cancer trial with bemcentinib and pacritinib

Thor Medical secures NOK90m loan from Innovation Norway

Adcentrx Therapeutics doses first patient in ADRX-0405 Phase 1a/b study

Norgine submits European marketing authorisation application filing for eflornithine

Nuvation Bio secures NMPA approval for taletrectinib in China

Nona Biosciences provides update on DualityBio's antibody-drug conjugate (ADC) collaboration with BeiGene

Hanx Biopharmaceuticals reports first patient dosed in Phase 1 clinical trial of HX044

Fapon Biopharma introduces FP008 immunotherapy for refractory cancers at Biotech Showcase

HUTCHMED announces NDA acceptance in China with priority review for ORPATHYS and TAGRISSO combination in lung cancer

Innovent and Roche agree exclusive global licence for novel DLL3 ADC

Kazia Therapeutics updates on paxalisib regulatory pathway after FDA meeting

McKesson completes sale of Rexall and Well.ca businesses to Birch Hill Equity Partners

CARsgen Therapeutics reveals positive CT041-ST-01 (NCT04581473) Phase II clinical trial results

Duality Biologics reveals B7H4 ADC milestone achievement and license exercise by BeiGene

Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial